Company Overview
Snapshot
Founded in January 2023 by Lee Shleifer and Moshe Haimann, SafeShot operates with 1–10 employees. The company has secured funding across one round from Headstart. In May 2023, SafeShot received funding from Headstart.
Business overview
SafeShot develops a compact, multi-use device designed to detect GHB (G) and ketamine in beverages. The underlying patent combines chemical and electronic components to trigger an alert to a user's cell phone and contact when drugs are detected. The company operates within the Agriculture & Food Technologies sector, specifically focusing on Food Tech and Food Trade & Services, targeting consumers in recreational and lifestyle settings, as well as the food retail and restaurant industries.
Strategic signal
In May 2023, SafeShot's innovative device for detecting date-rape drugs in beverages was highlighted by Geektime. This development signals a significant step in addressing safety concerns within the food and beverage industry, particularly in social environments. For investors, this indicates SafeShot's potential to disrupt the personal safety market with a tangible, patent-backed solution, positioning it as a relevant player in consumer protection and public health.
Log in to access full profile ›Company Intelligence Q&A
- What is SafeShot's core technology?
- SafeShot's core technology is a small, multi-use device that detects GHB and ketamine in drinks. It utilizes a patented chemical and electronic system that triggers an alert to a user's cell phone and contacts upon drug detection.
- When was SafeShot founded and by whom?
- SafeShot was founded in January 2023 by Lee Shleifer, who serves as Co-founder & CEO, and Moshe Haimann, Co-founder & COO.
- What markets does SafeShot target?
- SafeShot targets consumers in recreational and lifestyle settings, as well as businesses within the food retail and restaurant sectors, focusing on personal safety in the food and beverage industry.
- What is the current product stage of SafeShot?
- SafeShot is currently in the R&D product stage, developing its drug detection device.